Kestra Medical stockholder plans $97.9K sale

Kestra Medical Technologies, Ltd. (KMTS) stockholder Jeffrey Lawrence Schwartz filed a notice of proposed sale under Rule 144 for 3,890 common shares of KMTS through Merrill Lynch.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. (KMTS) stockholder Jeffrey Lawrence Schwartz filed a notice of proposed sale under Rule 144 for 3,890 common shares of KMTS through Merrill Lynch. The shares were acquired on September 4, 2026 via vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.

The proposed sale is tied to an aggregate market value of approximately $97,944.47. KMTS had 58,602,497 common shares outstanding as of the date referenced in the notice, which serves as context for the relative size of this planned disposition.

Key Figures

Shares to be sold: 3,890 shares Aggregate market value of securities to be sold: $97,944.47 Shares outstanding: 58,602,497 shares +2 more

5 metrics

Shares to be sold 3,890 shares Common shares of KMTS covered by the Rule 144 notice

Aggregate market value of securities to be sold $97,944.47 Value associated with the 3,890 KMTS common shares in the notice

Shares outstanding 58,602,497 shares KMTS common shares outstanding referenced in the notice

Acquisition date of shares September 4, 2026 Vesting date of restricted stock unit award yielding the shares

Proposed sale method Rule 144 sale through Merrill Lynch Broker listed: Merrill Lynch, 225 Liberty St, New York

Key Terms

Rule 144, restricted stock unit, equity compensation plan, common shares

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock unit financial

"Vesting of restricted stock unit award"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

common shares financial

"Common Shares | Merrill Lynch 225 Liberty St Floor 37"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

What does the Form 144 filing disclose for KMTS?

The filing discloses that a KMTS stockholder, Jeffrey Lawrence Schwartz, has filed a Rule 144 notice to sell 3,890 common shares of Kestra Medical Technologies, Ltd. through Merrill Lynch.

How many KMTS shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 3,890 common shares of KMTS. These shares are part of the issuer’s outstanding equity and represent a small portion relative to the 58,602,497 shares outstanding cited in the notice.

What is the approximate market value of the KMTS shares in this Form 144?

The proposed sale under Rule 144 relates to KMTS common shares with an aggregate market value of about $97,944.47, as indicated in the securities information section of the notice.

How were the KMTS shares in this Form 144 acquired?

The 3,890 KMTS common shares were acquired on September 4, 2026 through the vesting of a restricted stock unit award granted as part of Kestra Medical Technologies’ equity compensation plan.

What share count context does the Form 144 provide for KMTS?

The notice lists 58,602,497 KMTS common shares outstanding, providing context for the relative size of the planned sale of 3,890 shares under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 07:17 PM Accepted by SEC EDGAR 09/08/2026 - 07:16 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001702957
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kestra Medical Technologies, Ltd.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	425-279-8002
Name of Person for Whose Account the Securities are To Be Sold	Jeffrey Lawrence Schwartz
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	3890	97944.47	58602497	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	09/04/2026	Vesting of restricted stock unit award	Issuer			3890	09/04/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeffrey Schwartz
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)